High Growth Tech Stocks in Europe for April 2025

In This Article:

In the midst of escalating trade tensions and fluctuating consumer sentiment, European markets have experienced a turbulent period, with the pan-European STOXX Europe 600 Index ending 1.92% lower amid heightened vigilance from central banks. As investors navigate this complex landscape, identifying high growth tech stocks that can withstand market volatility becomes crucial; these companies often demonstrate resilience through innovation and adaptability in challenging economic climates.

Top 10 High Growth Tech Companies In Europe

Name

Revenue Growth

Earnings Growth

Growth Rating

Pharma Mar

24.24%

40.82%

★★★★★★

Yubico

20.08%

25.52%

★★★★★★

Elicera Therapeutics

63.53%

97.24%

★★★★★★

Devyser Diagnostics

26.28%

96.54%

★★★★★★

Xbrane Biopharma

33.71%

82.67%

★★★★★★

CD Projekt

33.78%

37.39%

★★★★★★

XTPL

97.45%

117.95%

★★★★★★

Skolon

29.76%

91.18%

★★★★★★

Elliptic Laboratories

49.76%

88.21%

★★★★★★

Ascelia Pharma

46.09%

66.93%

★★★★★★

Click here to see the full list of 230 stocks from our European High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

RaySearch Laboratories

Simply Wall St Growth Rating: ★★★★★☆

Overview: RaySearch Laboratories AB (publ) is a medical technology company that offers software solutions for cancer care across various regions including the Americas, Europe, Africa, the Asia-Pacific, and the Middle East, with a market cap of SEK7.71 billion.

Operations: The company generates revenue primarily from its healthcare software segment, amounting to SEK1.19 billion.

RaySearch Laboratories, a leader in advanced radiation therapy technology, has demonstrated robust financial and operational growth. In the past year, its earnings surged by 149.5%, significantly outpacing the Healthcare Services industry's growth of 28.2%. This performance is underpinned by strategic expansions such as the recent SEK 500 million equity offering and a significant new order from Heyou Hospital in China for its cutting-edge RayStation treatment planning system. These developments not only enhance RaySearch's market presence but also align with the growing demand for precise particle treatments in oncology—a sector where RaySearch is setting global standards. With an expected annual earnings growth of 23.7% over the next three years, RaySearch is well-positioned to maintain its trajectory amidst evolving healthcare technologies.

OM:RAY B Revenue and Expenses Breakdown as at Apr 2025
OM:RAY B Revenue and Expenses Breakdown as at Apr 2025

Sinch

Simply Wall St Growth Rating: ★★★★☆☆